Get started
Author

Joanna Leadbetter

Observed names: J Leadbetter, J. Leadbetter, Jo Leadbetter, Leadbetter, Joanna
Observed institutions: AstraZeneca (United Kingdom), Australasian Leukaemia and Lymphoma Group, Landcare Australia, Pharmaxis (Australia), Accurx Limited (United Kingdom), Eli Lilly (Australia), American Forests
ORCID: 0000-0002-0607-2975
Observed ORCID: 0000-0002-0607-2975
OpenAlex ID: A5004271838
Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126
2004 · Jeffrey L. Evelhoch, Patricia M. LoRusso, et al. · Clinical Cancer Research · 159
Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol
2005 · Helen C Swaisland, Malcolm Ranson, et al. · Clinical Pharmacokinetics · 158
Response and Relapse in Patients With Schizophrenia Treated With Olanzapine, Risperidone, Quetiapine, or Haloperidol: 12-Month Follow-Up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study
2005 · Martin Dossenbach, Cesar Arango-Dávila, et al. · The Journal of Clinical Psychiatry · 93
Bayesian decision procedures for dose‐escalation based on evidence of undesirable events and therapeutic benefit
2005 · John Whitehead, Yinghui Zhou, et al. · Statistics in Medicine · 43
Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial
2017 · K De Boeck, E Haarman, et al. · Journal of Cystic Fibrosis · 36
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG
2023 · Sun Loo, Andrew W. Roberts, et al. · Blood · 35
PDF
The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations
2021 · Asger Sverrild, Joanna Leadbetter, et al. · Respiratory Research · 24
PDF
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study
2021 · Patrick A. Flume, Elena Amelina, et al. · Journal of Cystic Fibrosis · 21
PDF
Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
2020 · Andrew H Wei, Glen A Kennedy, et al. · Blood · 18
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
2025 · Peter Youssef, Sabina Ciciriello, et al. · Rheumatology and Therapy · 16
PDF
A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis
2025 · Pankit Vachhani, Peter Tan, et al. · Haematologica · 14
PDF
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
2021 · Hedley Griffiths, Tegan Smith, et al. · The Journal of Rheumatology · 12
Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis
2019 · Emma Warren, Kristen Morgan, et al. · PharmacoEconomics · 7
A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan–lysyl oxidase inhibitor PXS-6302 in mature scars
2025 · Natalie Morellini, Peijun Gong, et al. · Science Translational Medicine · 4
PDF
Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
2024 · Peter Tan, Ross Baker, et al. · Blood · 4
PDF
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia
2024 · Geoffrey Littlejohn, Joanna Leadbetter, et al. · Clinical Rheumatology · 3
PDF
WS03.3 A phase II, randomised, double-blind, placebo-controlled, crossover study of dry powder mannitol in children with cystic fibrosis (CF)
2016 · K. De Boeck, E. Haarman, et al. · Journal of Cystic Fibrosis · 3
PDF
A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks
2025 · Ross Baker, Chih-Cheng Chen, et al. · Blood · 1
PDF
Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
2025 · Peter Youssef, Sabina Ciciriello, et al. · Rheumatology and Therapy · 1
PDF
WS14.2 Phase 3 randomised controlled study of the efficacy and safety of inhaled mannitol in adults with cystic fibrosis
2018 · E. Amelina, P. Flume, et al. · Journal of Cystic Fibrosis · 1
PDF
P.2.054 The clinical status of neuroleptic naive patientswith schizophrenia following monotherapy with olanzapine, risperidone or typical antipsychotics: A 12-month analysis
2004 · T. Treuer, G. Gál, et al. · European Neuropsychopharmacology · 1
The protocol for a phase 2A, multi centre, double-blind, randomized, placebo-controlled, parallel-group study to assess the effect of 12 weeks treatment with oral PXS-4728A on microglia activation, as measured by positron emission tomography, in participants with isolated rapid eye movement sleep behaviour disorder
2026 · Karolien Groenewald, Johannes C. Klein, et al. · Frontiers in Neurology
PDF
General Practice (GP) Text Messaging Support for Medication Adherence in Asthma and COPD Patients: A Randomised Controlled Trial
2024 · M. Gorobzov, V. Flahavan, et al. · American Journal of Respiratory and Critical Care Medicine
Pos1019 Real-world Evaluation of Treatment Patterns and Persistence of Tofacitinib in Treatment of Psoriatic Arthritis in Australia: an Analysis of the Opal Dataset.
2022 · G. Littlejohn, J. Leadbetter, et al. · Annals of the Rheumatic Diseases
PDF
Dr. Griffiths et al reply
2022 · Jo Leadbetter, Hedley Griffiths · The Journal of Rheumatology
PDF
Works count: 29
Citation count: 654
H-index: 12
I10-index: 12
Year
Topic
Type